Kintor Pharmaceutical Ltd
9939.HK
LATEST TRADE
69.00HKD
CHANGE
-2.80(-3.90%)
VOLUME
2,486,236
TODAY'S RANGE
68.00 - 72.10
52 WEEK RANGE
7.20 - 89.00
As of 1:08 AM PDT Sep 21 on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay
Previous Close71.80
Open71.55
Volume2,486,236
3M AVG Volume63.85
Today's High72.10
Today's Low68.00
52 Week High89.00
52 Week Low7.20
Shares Out (MIL)369.39
Market Cap (MIL)27,828.93
Forward P/E-38.13
Dividend (Yield %)--
9/21/2021
69.00
9939.HK
69.00
Advanced Charting
Next Event
Kintor Pharmaceutical Ltd Secondary Public Offering Lockup ExpirationOct 07, 2021
Latest Developments
More
12 days ago
Zhuhai Gree Group's Long Position In Kintor Pharmaceutical Falls To 6.77% - HKEX Filing
14 days ago
Kintor Pharmaceutical Expects To Commence Phase III Clinical Trial Of Kx-826 In China In Q4
21 days ago
Kintor Gets NMPA Approval For Trials Of Proxalutamide To Treat COVID-19 In China
About Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.
INDUSTRY
Biotechnology & Drugs
CONTACT INFO
No. 20 Songbei Road
Suzhou Industrial Park
SUZHOU, JNG
China
http://www.kintor.com.cn/
EXECUTIVE LEADERSHIP
Tong Youzhi
Executive Chairman of the Board, Chief Executive Officer
Lu Yan
Chief Financial Officer
Yan Mingming
Vice President of Sales
Zhou Guohao
Chief Medical Officer (USA)
Dong Xunwei
Chief Medical Officer
Key Stats
1.57 mean rating - 7 analysts
SELLHOLDBUY
REVENUE (MM, CNY)
2020
0.0K
2021(E)
0.0K
EPS (CNY)
2020
-1.640
2021(E)
-1.632
Price To Earnings (TTM)--
Price To Sales (TTM)--
Price To Book (MRQ)10.20
Price To Cash Flow (TTM)--
Total Debt To Equity (MRQ)6.47
LT Debt To Equity (MRQ)6.12
Return On Investment (TTM)-29.91
Return On Equity (TTM)-27.90
Latest News
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.
Apps​Newsletters​Advertise with UsAdvertising Guidelines​Cookies​Terms of UsePrivacyDo Not Sell My Personal Information
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All Rights Reserved.
U.S. job growth rose solidly in July amid demand for workers in the services industry